Baer M R, Bloomfield C D
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263.
Curr Opin Oncol. 1992 Feb;4(1):24-32. doi: 10.1097/00001622-199202000-00005.
Cytogenetic and molecular studies have assumed an increasing role in the evaluation and management of patients with leukemia. Many cytogenetic findings have become well established as important independent indicators of prognosis in the acute leukemias. There has been a recent explosion of knowledge about the genes involved in leukemogenesis and the manner in which their structure or expression is altered by chromosomal translocations or point mutations. Application of newer techniques such as the polymerase chain reaction and in situ hybridization has begun to allow quantitation of residual leukemia cells after therapy. Cytogenetic and molecular findings should allow us to use more individualized therapy in treating leukemia, as well as therapy targeting leukemia-specific abnormal gene products.
细胞遗传学和分子研究在白血病患者的评估与管理中发挥着越来越重要的作用。许多细胞遗传学发现已成为急性白血病重要的独立预后指标。最近，关于白血病发生过程中涉及的基因以及它们的结构或表达如何因染色体易位或点突变而改变的知识激增。聚合酶链反应和原位杂交等新技术的应用已开始能够对治疗后残留的白血病细胞进行定量分析。细胞遗传学和分子研究结果应使我们能够在治疗白血病时采用更具个体化的疗法，以及针对白血病特异性异常基因产物的疗法。
